- Tilray Brands reported an adjusted EBITDA of $10.2 million for Q1, which is a 9.1% increase year-over-year. However, it missed the estimate of $11 million.
- Net revenue for the quarter was $209.5 million, a 4.7% increase year-over-year, exceeding the estimate of $204.6 million.
- Cannabis revenue came in at $64.5 million, a 5.3% increase year-over-year but slightly below the estimated $65 million.
- Distribution revenue was $74.0 million, an 8.7% increase year-over-year, surpassing the estimate of $70.2 million.
- Beverage Alcohol revenue was $55.7 million, down 0.4% year-over-year but above the expected $53.9 million.
- Wellness revenue was reported at $15.2 million, up 3.3% year-over-year, but did not meet the estimate of $16 million.
- Tilray has cash and cash equivalents of $264.8 million, marking a 29% increase from the previous year.
- The company reiterates its fiscal year 2026 adjusted EBITDA outlook, projecting between $62 million and $72 million.
- Analyst recommendations include 2 buys and 9 holds, with no current sell recommendations.
A look at Tilray Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the Smartkarma Smart Scores for Tilray Inc, it paints a mixed picture for the company’s long-term outlook. With a strong momentum score of 5, Tilray seems to be performing well in terms of market trends and price movements. This indicates a positive upswing in investor interest and stock performance. On the other hand, Tilray scores lower in areas such as dividend, growth, and resilience, with scores of 1, 2, and 2 respectively. Despite these lower scores, Tilray’s solid value score of 4 suggests that the company may still be undervalued in the market, offering potential for future growth.
Overall, Tilray Inc, a pharmaceutical company specializing in cannabis-based medicines, appears to have a promising future based on its Smartkarma Smart Scores. While facing challenges in areas like dividend, growth, and resilience, the company excels in momentum, indicating strong market interest. With a solid value score, there is potential for Tilray to capitalize on its undervalued status and drive growth in the long term, making it a company to watch in the evolving cannabis industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
